Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
53 Results for "
Chemosensitizing
" in MedChemExpress (MCE) Product Catalog:
Products (53)
53 Results for "Chemosensitizing" in MCE Product Catalog:
Cat. No.: HY-184928
CAS No.: 3099381-90-2
S34-1040 is an AKR1C3 inhibitor with a human IC50 of 0.03 μM and exhibits no detectable inhibition of AKR1C1, AKR1C2, or AKR1C4. S34-1040 functions as a chemosensitizer and restores sensitivity of doxorubicin-resistant breast cancer cells to doxorubicin. S34-1040 can be used for the research of doxorubicin-resistant breast cancer .
Cat. No.: HY-182633
CAS No.: 159542-04-8
Target:
Research Areas:
Hapalosin is a multidrug resistance reversal agent and chemosensitizer with mild cytotoxicity against cancer cells. Hapalosin inhibits the ATP-dependent drug efflux pump function of P-glycoprotein and antagonizes multidrug resistance-associated proteins. Hapalosin reverses multidrug resistance mediated by P-glycoprotein and multidrug resistance-associated proteins, increases the intracellular accumulation of drugs transported by P-glycoprotein, and enhances the cytotoxicity of these drugs against cancer cells overexpressing P-glycoprotein. Hapalosin can be used in the research of multidrug-resistant cancers .
Cat. No.: HY-189206
Target:
Akt mTOR CDK PD-1/PD-L1 Apoptosis DNA/RNA Synthesis Cadherin
Research Areas:
MM129 is an anticancer agent. MM129 inhibits key oncogenic signaling molecules such as AKT, mTOR, and CDK2, and downregulates the expression of PD-L1. MM129 induces cell cycle arrest. MM129 induces Apoptosis. MM129 induces DNA damage. MM129 induces oxidative stress. MM129 exhibits chemosensitizing properties. MM129 restores the expression of E-cadherin. MM129 can be used in the research of colorectal cancer .
Cat. No.: HY-184148
Target:
Research Areas:
PFKFB3-IN-3 is a selective PFKFB3 inhibitor with a Ki value of 0.09 μM. PFKFB3-IN-3 reduces cancer cell viability, inhibits tumor growth in xenograft models, and acts as a chemosensitizer to exert synergistic effects with chemotherapeutic agents. The limited cellular activity of PFKFB3-IN-3 restricts its application as a chemical probe, but it demonstrates that the Cys154 residue of PFKFB3 is druggable. PFKFB3-IN-3 can be used for the research of pancreatic ductal adenocarcinoma .
Cat. No.: HY-103721R
CAS No.: 891002-11-2
Target:
Research Areas:
SIRT6-IN-2 (Standard) is the analytical standard of SIRT6-IN-2 (HY-103721). This product is intended for research and analytical applications. SIRT6-IN-2 (Compound 5) is a selective and competitive SIRT6 inhibitor (IC50: 34 μM). SIRT6-IN-2 increases acetylation of H3K9 and increases glucose uptake in cultured cells. SIRT6-IN-2 also reduces T cell proliferation. SIRT6-IN-2 has immunosuppressive and chemosensitizing effects .
Cat. No.: HY-183143
CAS No.: 1392014-36-6
Research Areas:
Lss-11 is a topoisomerase inhibitor. LSS-11 enhances cell death in cancer cells by inducing apoptosis through increasing the DR5 protein level and PARP1 cleavage. LSS-11 dose-dependently reduces STAT3 phosphorylation, downregulates its target genes MDR1 and MRP1, reduces P-gp protein expressionwithout affecting P-gp transport function. Lss-11 is a chemosensitizer and shows synergistic anticancer effect with Paclitaxel (HY-B0015). Lss-11 can be used for the research of paclitaxel-resistant lung cancer .
Cat. No.: HY-P11678
CAS No.: 2390474-88-9
Cat. No.: HY-111193A
CAS No.: 52423-57-1
Synonyms: 3-Chloroprocainamide hydrochloride
Research Areas:
Declopramide (3-Chloroprocainamide) hydrochloride is an orally active, blood-brain barrier-permeable IκBβ/NF-κB inhibitor and chemosensitizer. Declopramide exhibits affinity for rabbit 5-HT3 receptors (5-HT3R) with a Ki value of 3.2 μM. Declopramide inhibits IκBβ degradation, blocks NFκB activation, and induces rapid apoptosis and DNA strand breaks in cancer cells. Declopramide enhances the cytotoxicity induced by Cisplatin (HY-17394) and is also metabolically converted to N-acetyl declopramide. Declopramide can be used in the research of tumors such as brain astrocytoma .
Cat. No.: HY-128299
CAS No.: 324777-01-7
Target:
Research Areas:
ALDH3A1-IN-4 is a selective ALDH3A1 inhibitor with an IC50 of 0.2 μM. ALDH3A1-IN-4 binds to the aldehyde-binding pocket of ALDH3A1 via hydrophobic interactions and van der Waals forces. ALDH3A1-IN-4 acts as a chemosensitizer that sensitizes ALDH3A1-expressing cancer cells to the antiproliferative effect of mafosfamide, but does not produce a sensitizing effect on non-cancer cells that do not express ALDH3A1. ALDH3A1-IN-4 is applicable to research related to lung adenocarcinoma and glioblastoma .
Cat. No.: HY-188136
Target:
Research Areas:
ASO-4625 is a 20-nucleotide gapmer antisense oligonucleotide with a full phosphorothioate backbone and 2'-O-(2-methoxy) ethyl ribose modifications, which targets BCL2 mRNA and BCL2L1 mRNA. ASO-4625 downregulates Bcl-2 expression via an RNase H-dependent antisense mechanism with 100% complementarity, and downregulates Bcl-xL expression via the same mechanism with three mismatches. ASO-4625 induces Apoptosis and acts as a chemosensitizer. ASO-4625 does not significantly modulate the expression of Bcl-W, survivin, Akt, or p53 mRNA. ASO-4625 can be used in studies of breast cancer and non-small cell lung cancer .
Cat. No.: HY-119225
CAS No.: 67427-51-4
Target:
Research Areas:
CBP-93872 is a G2 checkpoint inhibitor and a chemosensitizer. CBP-93872 specifically inhibits DNA double-strand break (DSB)-dependent, Nbs1-mediated ATR activation, without directly inhibiting ATR kinase activity or affecting ATR activation induced by other types of DNA damage; meanwhile, it suppresses the pathway between ATM and ATR activation, thereby reducing the autophosphorylation of ATR and the subsequent phosphorylation of Chk1. CBP-93872 does not inhibit DNA end resection at DSB sites. CBP-93872 induces cell death and enhances the cytotoxic effects of platinum-containing compounds and pyrimidine antimetabolites on cancer cells. CBP-93872 can be used in related research on p53-mutant cancers, colorectal cancer, and pancreatic cancer .
Cat. No.: HY-100468R
CAS No.: 1979192-13-6
Target:
Research Areas:
REV7/REV3L-IN-1 (Standard) is the analytical standard of REV7/REV3L-IN-1 (HY-100468). This product is intended for research and analytical applications. REV7/REV3L-IN-1 is a REV7/REV3L interaction inhibitor with an IC50 of 78 μM. REV7/REV3L-IN-1 binds directly to REV7 and inhibits its interaction with REV3L. REV7/REV3L-IN-1 inhibits interstrand crosslink repair in cells. REV7/REV3L-IN-1 chemosensitizes cancer cells to Cisplatin (HY-17394). REV7/REV3L-IN-1 can be used in cervical cancer research .
Cat. No.: HY-109061A
CAS No.: 2411549-88-5
Synonyms: YH25448 mesylate hydrate; GNS-1480 mesylate hydrate
Lazertinib (YH25448; GNS-1480) mesylate hydrate is an orally active, blood-brain barrier permeable third-generation EGFR tyrosine kinase inhibitor, as well as an ABCB1/ABCG2 inhibitor and a TRPA1 activator. Lazertinib mesylate hydrate exhibits IC50 values of 0.4 mM and 0.2 mM against human ABCB1 and ABCG2, respectively. By inhibiting mutant EGFR signaling, EGFR phosphorylation and the downstream ERK/AKT pathway, as well as upregulating surface expression of EGFR/MET, Lazertinib mesylate hydrate induces cell cycle arrest, apoptosis, spontaneous calcium responses, hyperexcitability of dorsal root ganglion (DRG) neurons, and TRPA1-dependent pain-like behaviors. Lazertinib mesylate hydrate competitively binds to the substrate-binding sites of ABCB1/ABCG2, stimulates their ATPase activity without altering their expression or plasma membrane localization, thereby enhancing ADCC activity, acting as a chemosensitizer, and reversing ABCB1-mediated multidrug resistance. It exerts antitumor activity as a single agent or in combination with other drugs. Lazertinib mesylate hydrate is applicable to research related to non-small cell lung cancer, multidrug-resistant cancers, and paresthesia .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
